Russell Dahl ’97, CEO and Founder of Neurodon Corporation has entered into a 2-year partnership with JDRF to discover new therapeutic candidates to treat type 1 diabetes (T1D). The project builds on Dr. Dahl’s pioneering work developing molecules that alleviate a condition known as endoplasmic reticulum stress, a key driver of beta cell dysfunction and loss in T1D. Also participating in the collaboration are the Indiana University School of Medicine and the Universite Libre de Bruxelles.